US Patent 10213390 Treatment of fragile X syndrome with cannabidiol
Patent 10213390 was granted and assigned to Zynerba Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 23 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Jun, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+313 characters)
Article
Patent abstract
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Donna Gutterman0
John Messenheimer0
Marcel Bonn-Miller0
Nancy Tich0
Terri Sebree0
Edits on 7 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 8 Oct, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10213390 Treatment of fragile X syndrome with cannabidiol
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10213390
Date of patent
February 26, 2019
Patent application number
16144632
Date Filed
September 27, 2018
Patent primary examiner
Find more entities like US Patent 10213390 Treatment of fragile X syndrome with cannabidiol
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
